A Choudhury1,2, A Jindal1,2, R Maiwall1,2, M K Sharma1,2, B C Sharma1,2, V Pamecha1, M Mahtab3, S Rahman3, Y K Chawla4, S Taneja4, S S Tan5, H Devarbhavi6, Z Duan7, Chen Yu7, Q Ning8, Ji Dong Jia9, D Amarapurkar10, C E Eapen11, A Goel11, S S Hamid12, A S Butt12, W Jafri12, D J Kim13, H Ghazinian14, G H Lee15, Ajit Sood16, L A Lesmana17, Z Abbas18, G Shiha19, D A Payawal20, A K Dokmeci21, J D Sollano22, G Carpio22, G K Lau23, F Karim24, P N Rao25, R Moreau26, P Jain1,2, P Bhatia1,27, G Kumar1,2, S K Sarin28,29. 1. Department of Hepatology and Transplant, Institute of Liver and Biliary Sciences (ILBS), New Delhi, 110 070, India. 2. Department of Hepatology, Institute of Liver and Biliary Sciences (ILBS), New Delhi, 110 070, India. 3. Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. 4. Department of Hepatology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. 5. Department of Gastroenterology and Hepatology, Selayang Hospital, Kepong, Malaysia. 6. Department of Gastroenterology and Hepatology, St John Medical College, Bangalore, India. 7. Beijing Youan Hospital, Capital Medical University, Beijing, China. 8. Department of Infectious Disease, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China. 9. Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China. 10. Department of Gastroenterology and Hepatology, Bombay Hospital and Medical Research Centre, Mumbai, India. 11. Department of Gastrointestinal Sciences, Christian Medical College, Vellore, India. 12. Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan. 13. Hallym University Chuncheon Sacred Heart Hospital, Center for Liver and Digestive Diseases, Chuncheon, Gangwon-Do, Republic of Korea. 14. Department of Hepatology, Nork Clinical Hospital of Infectious Diseases, Yerevan, Armenia. 15. Department of Gastroenterology and Hepatology, National University Health System, Singapore, Singapore. 16. Department of Gastroenterology, Dayanand Medical College, Ludhiana, India. 17. Division of Hepatology, University of Indonesia, Jakarta, Indonesia. 18. Department of Hepatogastroenterology, Sindh Institute of Urology and Transplantation, Karachi, Pakistan. 19. Department of Internal Medicine, Egyptian Liver Research Institute and Hospital, Cairo, Egypt. 20. Department of Hepatology, Cardinal Santos Medical Center, Manila, Philippines. 21. Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey. 22. Cardinal Santos Medical Center, Metro Manila, Philippines. 23. The Institute of Translational Hepatology, Beijing, China. 24. Sir Salimur Rehman Medical College, Mitford Hospital, Dhaka, Bangladesh. 25. Asian Institute of Gastroenterology, Hyderabad, India. 26. Inserm, U1149, Centre de recherche sur l'Inflammation (CRI), UMR_S 1149, Labex INFLAMEX, Université Paris Diderot Paris 7, Paris, France. 27. Department of Clinical Research, Institute of Liver and Biliary Sciences (ILBS), New Delhi, 110 070, India. 28. Department of Hepatology and Transplant, Institute of Liver and Biliary Sciences (ILBS), New Delhi, 110 070, India. shivsarin@gmail.com. 29. Department of Hepatology, Institute of Liver and Biliary Sciences (ILBS), New Delhi, 110 070, India. shivsarin@gmail.com.
Abstract
BACKGROUND AND AIMS: Acute-on-chronic liver failure (ACLF) is a progressive disease associated with rapid clinical worsening and high mortality. Early prediction of mortality and intervention can improve patient outcomes. We aimed to develop a dynamic prognostic model and compare it with the existing models. METHODS: A total of 1402 ACLF patients, enrolled in the APASL-ACLF Research Consortium (AARC) with 90-day follow-up, were analyzed. An ACLF score was developed in a derivation cohort (n = 480) and was validated (n = 922). RESULTS: The overall survival of ACLF patients at 28 days was 51.7%, with a median of 26.3 days. Five baseline variables, total bilirubin, creatinine, serum lactate, INR and hepatic encephalopathy, were found to be independent predictors of mortality, with AUROC in derivation and validation cohorts being 0.80 and 0.78, respectively. AARC-ACLF score (range 5-15) was found to be superior to MELD and CLIF SOFA scores in predicting mortality with an AUROC of 0.80. The point scores were categorized into grades of liver failure (Gr I: 5-7; II: 8-10; and III: 11-15 points) with 28-day cumulative mortalities of 12.7, 44.5 and 85.9%, respectively. The mortality risk could be dynamically calculated as, with each unit increase in AARC-ACLF score above 10, the risk increased by 20%. A score of ≥11 at baseline or persisting in the first week was often seen among nonsurvivors (p = 0.001). CONCLUSIONS: The AARC-ACLF score is easy to use, dynamic and reliable, and superior to the existing prediction models. It can reliably predict the need for interventions, such as liver transplant, within the first week.
BACKGROUND AND AIMS: Acute-on-chronic liver failure (ACLF) is a progressive disease associated with rapid clinical worsening and high mortality. Early prediction of mortality and intervention can improve patient outcomes. We aimed to develop a dynamic prognostic model and compare it with the existing models. METHODS: A total of 1402 ACLF patients, enrolled in the APASL-ACLF Research Consortium (AARC) with 90-day follow-up, were analyzed. An ACLF score was developed in a derivation cohort (n = 480) and was validated (n = 922). RESULTS: The overall survival of ACLF patients at 28 days was 51.7%, with a median of 26.3 days. Five baseline variables, total bilirubin, creatinine, serum lactate, INR and hepatic encephalopathy, were found to be independent predictors of mortality, with AUROC in derivation and validation cohorts being 0.80 and 0.78, respectively. AARC-ACLF score (range 5-15) was found to be superior to MELD and CLIF SOFA scores in predicting mortality with an AUROC of 0.80. The point scores were categorized into grades of liver failure (Gr I: 5-7; II: 8-10; and III: 11-15 points) with 28-day cumulative mortalities of 12.7, 44.5 and 85.9%, respectively. The mortality risk could be dynamically calculated as, with each unit increase in AARC-ACLF score above 10, the risk increased by 20%. A score of ≥11 at baseline or persisting in the first week was often seen among nonsurvivors (p = 0.001). CONCLUSIONS: The AARC-ACLF score is easy to use, dynamic and reliable, and superior to the existing prediction models. It can reliably predict the need for interventions, such as liver transplant, within the first week.
Entities:
Keywords:
AARC score; ACLF; Cirrhosis; Liver failure; Organ failure
Authors: Thierry Gustot; Javier Fernandez; Elisabet Garcia; Filippo Morando; Paolo Caraceni; Carlo Alessandria; Wim Laleman; Jonel Trebicka; Laure Elkrief; Corinna Hopf; Pablo Solís-Munoz; Faouzi Saliba; Stefan Zeuzem; Augustin Albillos; Daniel Benten; José Luis Montero-Alvarez; Maria Teresa Chivas; Mar Concepción; Juan Córdoba; Aiden McCormick; Rudolf Stauber; Wolfgang Vogel; Andrea de Gottardi; Tania M Welzel; Marco Domenicali; Alessandro Risso; Julia Wendon; Carme Deulofeu; Paolo Angeli; François Durand; Marco Pavesi; Alexander Gerbes; Rajiv Jalan; Richard Moreau; Pere Ginés; Mauro Bernardi; Vicente Arroyo Journal: Hepatology Date: 2015-05-29 Impact factor: 17.425
Authors: Rajiv Jalan; Marco Pavesi; Faouzi Saliba; Alex Amorós; Javier Fernandez; Peter Holland-Fischer; Rohit Sawhney; Rajeshwar Mookerjee; Paolo Caraceni; Richard Moreau; Pere Ginès; Francois Durand; Paolo Angeli; Carlo Alessandria; Wim Laleman; Jonel Trebicka; Didier Samuel; Stefan Zeuzem; Thierry Gustot; Alexander L Gerbes; Julia Wendon; Mauro Bernardi; Vicente Arroyo Journal: J Hepatol Date: 2014-11-22 Impact factor: 25.083
Authors: Richard Moreau; Rajiv Jalan; Pere Gines; Marco Pavesi; Paolo Angeli; Juan Cordoba; Francois Durand; Thierry Gustot; Faouzi Saliba; Marco Domenicali; Alexander Gerbes; Julia Wendon; Carlo Alessandria; Wim Laleman; Stefan Zeuzem; Jonel Trebicka; Mauro Bernardi; Vicente Arroyo Journal: Gastroenterology Date: 2013-03-06 Impact factor: 22.682
Authors: Rajiv Jalan; Faouzi Saliba; Marco Pavesi; Alex Amoros; Richard Moreau; Pere Ginès; Eric Levesque; Francois Durand; Paolo Angeli; Paolo Caraceni; Corinna Hopf; Carlo Alessandria; Ezequiel Rodriguez; Pablo Solis-Muñoz; Wim Laleman; Jonel Trebicka; Stefan Zeuzem; Thierry Gustot; Rajeshwar Mookerjee; Laure Elkrief; German Soriano; Joan Cordoba; Filippo Morando; Alexander Gerbes; Banwari Agarwal; Didier Samuel; Mauro Bernardi; Vicente Arroyo Journal: J Hepatol Date: 2014-06-17 Impact factor: 25.083
Authors: Karen Y Xiao; Rebecca A Hubbard; David E Kaplan; Tamar H Taddei; David S Goldberg; Nadim Mahmud Journal: Hepatol Int Date: 2020-06-09 Impact factor: 6.047
Authors: Sumeet K Asrani; James Trotter; Jack Lake; Aijaz Ahmed; Anthony Bonagura; Andrew Cameron; Andrea DiMartini; Stevan Gonzalez; Gene Im; Paul Martin; Philippe Mathurin; Jessica Mellinger; John P Rice; Vijay H Shah; Norah Terrault; Anji Wall; Scott Winder; Goran Klintmalm Journal: Liver Transpl Date: 2020-01 Impact factor: 5.799